Trial Profile
Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Temozolomide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine carcinoma
- Focus Therapeutic Use
- 18 Dec 2019 Status changed from active, no longer recruiting to completed.
- 17 Nov 2019 This trial has been completed in Swedena and Denmark (Global End Date: 28 May 2019), according to European Clinical Trials Database.
- 21 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.